StrictosamideCAS# 23141-25-5 |
- Vincosamide
Catalog No.:BCN5081
CAS No.:23141-27-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 23141-25-5 | SDF | Download SDF |
PubChem ID | 10345799 | Appearance | Powder |
Formula | C26H30N2O8 | M.Wt | 498.5 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
SMILES | C=CC1C2CC3C4=C(CCN3C(=O)C2=COC1OC5C(C(C(C(O5)CO)O)O)O)C6=CC=CC=C6N4 | ||
Standard InChIKey | LBRPLJCNRZUXLS-IUNANRIWSA-N | ||
Standard InChI | InChI=1S/C26H30N2O8/c1-2-12-15-9-18-20-14(13-5-3-4-6-17(13)27-20)7-8-28(18)24(33)16(15)11-34-25(12)36-26-23(32)22(31)21(30)19(10-29)35-26/h2-6,11-12,15,18-19,21-23,25-27,29-32H,1,7-10H2/t12-,15+,18+,19-,21-,22+,23-,25+,26+/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Strictosamide may have important effects on inflammation and inflammatory pain. 2. Strictosamide is slightly toxic to Charles River mouse (LD(50)=723.17 mg/kg), producing CNS depression and kidney toxicity. 3. Strictosamide has nonsignificant in vitro and in vivo effect on kidney Na(+),K(+)-ATPase activity but produced an in vivo increase of Na(+),K(+)-ATPase activity of brain. 4. Strictosamide possesses antibacterial and antiviral activities. |
Targets | Sodium Channel | ATPase | Potassium Channel | Immunology & Inflammation related | Antifection | Influenza virus |
Strictosamide Dilution Calculator
Strictosamide Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.006 mL | 10.0301 mL | 20.0602 mL | 40.1204 mL | 50.1505 mL |
5 mM | 0.4012 mL | 2.006 mL | 4.012 mL | 8.0241 mL | 10.0301 mL |
10 mM | 0.2006 mL | 1.003 mL | 2.006 mL | 4.012 mL | 5.015 mL |
50 mM | 0.0401 mL | 0.2006 mL | 0.4012 mL | 0.8024 mL | 1.003 mL |
100 mM | 0.0201 mL | 0.1003 mL | 0.2006 mL | 0.4012 mL | 0.5015 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Physalin B
Catalog No.:BCN7921
CAS No.:23133-56-4
- Heveaflavone
Catalog No.:BCN5079
CAS No.:23132-13-0
- Tectorigenin 7-O-xylosylglucoside
Catalog No.:BCN2903
CAS No.:231288-19-0
- 6'-O-xylosyl-glycitin
Catalog No.:BCN8169
CAS No.:231288-18-9
- Mudanpioside H
Catalog No.:BCC9049
CAS No.:231280-71-0
- 5-(4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl)furan-2-carbaldehyde
Catalog No.:BCC8719
CAS No.:231278-84-5
- N-[3-Chloro-4-(3-fluorobenzyloxy)phenyl]-6-iodoquinazolin-4-amine
Catalog No.:BCC9068
CAS No.:231278-20-9
- Lapatinib
Catalog No.:BCC3633
CAS No.:231277-92-2
- Methylxanthoxylin
Catalog No.:BCC8212
CAS No.:23121-32-6
- Fumagillin
Catalog No.:BCC2347
CAS No.:23110-15-8
- UK 370106
Catalog No.:BCC2379
CAS No.:230961-21-4
- UK 356618
Catalog No.:BCC2378
CAS No.:230961-08-7
- Vincosamide
Catalog No.:BCN5081
CAS No.:23141-27-7
- Pentoxyverine Citrate
Catalog No.:BCC4697
CAS No.:23142-01-0
- Oxymetazoline HCl
Catalog No.:BCC4333
CAS No.:2315-02-8
- H-Glu(OMe)-OMe.HCl
Catalog No.:BCC2932
CAS No.:23150-65-4
- 3,4-Dimethoxycinnamic acid
Catalog No.:BCN5040
CAS No.:2316-26-9
- Pyrolatin
Catalog No.:BCN8439
CAS No.:23176-70-7
- Nervosine
Catalog No.:BCN2012
CAS No.:23179-26-2
- Songoramine
Catalog No.:BCN6474
CAS No.:23179-78-4
- Senkirkine
Catalog No.:BCN2136
CAS No.:2318-18-5
- Simiarenone
Catalog No.:BCN5082
CAS No.:2318-78-7
- Paeoniflorin
Catalog No.:BCN6301
CAS No.:23180-57-6
- Columbianetin acetate
Catalog No.:BCN2652
CAS No.:23180-65-6
Synthesis and Biological Evaluation of Strictosamide Derivatives with Improved Antiviral and Antiproliferative Activities.[Pubmed:25589048]
Chem Biol Drug Des. 2015 Oct;86(4):523-30.
A series of novel derivatives of Strictosamide were synthesized and biologically evaluated. Most of the new compounds exhibited improved activities than the parent compound Strictosamide. Among them, compounds Ib and If possessed antiviral activities against influenza A virus (A/Jinan/15/90) with IC50 values of 4.12 and 12.35 mug/mL, respectively. Compound Ie possessed antiviral activity against respiratory syncytial virus (RSV) with an IC50 value of 9.58 mug/mL. Both compounds IIc and IId had moderate antiproliferative effects against five human cancer cell lines. The preliminary structure-activity relationships were also concluded. This study provides a promising new template with potential antiviral activity.
Effects of strictosamide on mouse brain and kidney Na+, K+-ATPase and Mg2+-ATPase activities.[Pubmed:18992802]
J Ethnopharmacol. 2009 Jan 12;121(1):117-22.
Present study reports on the general bioactivity of Strictosamide and on its effects on Na(+),K(+)-ATPase and Mg(2+)-ATPase activities of Charles River male mouse. Strictosamide is the main glycoalkaloid of Sarcocephalus latifolius (Rubiaceae) leaves and roots, used as medicinal plant in folk medicine. In this work, we studied the in vitro effects of various concentrations of Strictosamide (0.25, 0.5, 1 or 2 mg/mL) and the in vivo effects of single doses (50, 100 or 200 mg/kg, i.p.) of this compound on kidney and brain Na(+),K(+)-ATPase and Mg(2+)-ATPase activities. Results of general study showed that Strictosamide is slightly toxic to Charles River mouse (LD(50)=723.17 mg/kg), producing CNS depression and kidney toxicity, but the exact mechanism of these effects could not be defined. Strictosamide inhibited the in vitro and in vivo Mg(2+)-ATPase activity on kidney but had nonsignificant effect on brain. Furthermore, Strictosamide had nonsignificant in vitro and in vivo effect on kidney Na(+),K(+)-ATPase activity but produced an in vivo increase of Na(+),K(+)-ATPase activity of brain, these findings suggesting that strictosamine may be related to the induction of alpha(2) isoform of Na(+),K(+)-ATPase and may account for the folk use of Sarcocephalus latifolius root infusion on hypertension.
In vivo anti-inflammatory and analgesic activities of strictosamide from Nauclea officinalis.[Pubmed:25026342]
Pharm Biol. 2014 Nov;52(11):1445-50.
CONTEXT: Strictosamide is the main representative constituent of Nauclea officinalis Pierre ex Pitard (Rubiaceae), which has been used for a long time in China to treat diseases related to infection and inflammation, but its pharmacological activities are not well studied. OBJECTIVE: This work evaluates the anti-inflammatory and analgesic activities of Strictosamide by in vivo experiments. MATERIALS AND METHODS: The anti-inflammatory activity was assessed in mice by models of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced ear edema, acetic acid-elevated vascular permeability, and carboxymethylcellulose sodium (CMC-Na)-induced leukocyte migration. The analgesic activity was estimated in mice using acetic acid-induced writhing and hot-plate tests. Compound was injected to mice twice a day for 3 d at doses of 10, 20, and 40 mg/kg. RESULTS: At 20 and 40 mg/kg, Strictosamide obviously decreased the TPA-induced mice ear edema (24.7 and 28.1% inhibition, respectively), and significantly inhibited acetic acid-stimulated peritoneal vascular permeability in mice (23.3 and 33.4% inhibition, respectively). It also significantly decreased the leukocytes in the mice peritoneal cavity induced by CMC-Na at all the tested doses (46.0, 49.1, and 58.7% inhibition, respectively). To acetic acid-induced writhing test in mice, Strictosamide markedly prolonged the pain latency at 20 and 40 mg/kg and decreased the writhing counts at 40 mg/kg (49.7% inhibition). However, it did not obviously improve the pain threshold of mice in hot-plate test. DISCUSSION AND CONCLUSION: Strictosamide may have important effects on inflammation and inflammatory pain. The results provide scientific support for the role of Strictosamide in the use of N. officinalis to treat inflammatory diseases.